SAN FRANCISCO — Mylan’s CEO gave a measured response to President-elect Trump’s promise Wednesday morning to crack down on high drug prices.
Heather Bresch, who spent the last half of 2016 under fire for raising the price of the company’s EpiPen allergy shot 400 percent, said she would have to see the entire picture of what Trump is suggesting before pronouncing judgment.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.